





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APR 1 9 2002

Applicant: Wallner et al.

Art Unit

: 1644

Serial No.: 09/730,465

Examiner: P. Gambel

TECH CENTER 1600/2900

Filed Title

: December 5, 2000

: METHOD OF PROPHYLAXIS OR TREATMENT OF ANTIGEN PRESENTING

CELL DRIVEN SKIN CONDITIONS USING INHIBITORS OF THE CD2/LFA-3

INTERACTION

Commissioner for Patents Washington, D.C. 20231

## RESPONSE TO SPECIES ELECTION REQUIREMENT

Responsive to the requirement for species election mailed March 7, 2002, applicants elect soluble LFA-3 (species of agent) and psoriasis (species of skin condition) for prosecution on the merits. Claims 1, 3, 5-7, 20, 22-32, 34-38, 41-44 and 49-54 read on the elected species. Applicants note that soluble LFA-3 encompasses all soluble LFA-3 fusion proteins. The election is made without traverse.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Louis Myers

Reg. No. 35,965

Fish & Richardson P.C. 225 Franklin Street

Boston, Massachusetts 02110-2804

Telephone: (617) 542-5070 Facsimile: (617) 542-8906

20416780.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

a Tuvines, Reg. Vo. 50, 63.

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

Signature

Typed or Printed Name of Person Signing Certificate